Mechanistically, Alivec binds tropomyosin 3 (Tpm3) and heterogeneous nuclear ribonucleoprotein A2/B1 (Hnrnpa2b1) to regulate chondrogenic transformation of VSMCs implicated in vascular dysfunction and hypertension. The gene discussed is TPM3; the disease is hypertensive disorder.